Use of a compound having a coumarin structure in the preparation of a drug for preventing, alleviating and / or treating obesity and / or fatty liver disease
By using the coumarin-structured compound 1-(4-(benzylamino)-2-oxo-2H-benzopyran-3-yl)-3-(3-chlorophenyl)urea, the treatment challenges of non-alcoholic fatty liver disease and obesity have been solved, achieving significant improvement in liver damage and hepatoprotective effects.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- GANNAN INST OF INNOVATION & TRANSLATIONAL MEDICINE
- Filing Date
- 2026-05-29
- Publication Date
- 2026-07-17
AI Technical Summary
Currently, there are no effective drugs for treating non-alcoholic fatty liver disease (NAFLD), and obesity is strongly associated with NAFLD. Existing technologies have failed to effectively prevent and treat these two diseases.
The compound 1-(4-(benzylamino)-2-oxo-2H-benzopyran-3-yl)-3-(3-chlorophenyl)urea, which has a coumarin structure, is used to prepare a drug for the prevention and treatment of obesity and non-alcoholic fatty liver disease. It improves liver tissue structure by inhibiting liver damage caused by a high-fat, high-cholesterol diet.
It significantly reduces serum ALT and AST levels, improves hepatocyte morphology, and alleviates steatosis and hydropic degeneration, demonstrating good hepatoprotective effects and showing therapeutic potential for non-alcoholic fatty liver disease.
Smart Images
Figure CN122398787A_ABST